Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
49 Items
Title  Creator  Group name  Publishing year 
Why Is Wnt/?-Catenin Not Yet Targeted in Routine Cancer Care? de Pellegars-Malhortie et al. EquipeMY 2024-07-16
Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study Adenis et al. EquipeMY 2024-09
Prognostic value of the tumor-to-liver density ratio in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy. A post-hoc study of the STIC-AVASTIN trial Mazard et al. EquipeMY 2024-06-17
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study Flecchia et al. EquipeMY 2024-02
Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer Mirandola et al. EquipeMY 2024-09-19
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2023-02-02
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells Cherradi et al. EquipeMY 2023-04-11
GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol Rouanet et al. EquipeMY 2023-10
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort Taïeb et al. EquipeMY 2023-04-23
Comparison of the structures and topologies of plasma extracted circulating nuclear and mitochondrial cell-free DNA Pisareva et al. EquipeMY 2023
A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer Grosgeorges et al. EquipeMY 2023-02-15
[hPG80 and cancer: A new blood biomarker in development for patient monitoring] You et al. EquipeMY 2022-06
Triplet chemotherapy in combination with anti-EGFR agents for the treatment of metastatic colorectal cancer: Current evidence, advances, and future perspectives Folprecht et al. EquipeMY 2022-01
The desmoplastic growth pattern is associated with second-stage completion and longer survival in 2-stage hepatectomy for colorectal cancer liver metastases Khellaf et al. EquipeMY 2022-09-08
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study Bordeau et al. EquipeJPP 2022-12-20
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial Cousin et al. EquipeMY 2022-02
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma Quesada et al. EquipeMY 2022-01
Neutrophil extracellular traps have auto-catabolic activity and produce mononucleosome-associated circulating DNA Pisareva et al. EquipeMY 2022-11-28
Mechanical signatures of human colon cancers Lopez-Crapez et al. EquipeJC 2022-07-21
Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study Rousseau et al. EquipeMY 2022-06
Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer Pastor et al. EquipeMY 2022-02-18
Assessment of Dendrigrafts of Poly- l -lysine Cytotoxicity and Cell Penetration in Cancer Cells Granier et al. EquipeMY 2022-02-11
Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment Pastor et al. EquipeMY 2021-09
Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy Kerckhove et al. EquipeMY 2021
Circulating nuclear DNA structural features, origins, and complete size profile revealed by fragmentomics Sanchez et al. EquipeMY 2021-04-08
12>>>
49 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés